A Shift In Thinking: FDA Moves Toward Easier Neurofibromatosis Endpoints
Volumetric imaging gains favor as a primary endpoint, along with single-arm studies, potentially creating a faster path to drug approval in the rare disease.
You may also be interested in...
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.